Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases

References

• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250. doi:10.1056/NEJMoa2107456
   PubMed Web of Science ®Google Scholar
• Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355–1371. doi:10.1056/NEJMoa2110362
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847–860. doi:10.1056/NEJMoa2117608
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348–2360. doi:10.1056/NEJMoa2105290
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531–543. doi:10.1056/NEJMoa2116185
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45. doi:10.1001/jama.2021.8565
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884. doi:10.1056/NEJMoa2107715
   PubMed Web of Science ®Google Scholar
• Fan YJ, Chan KH, Hung IF. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines. 2021;9(9):989. doi:10.3390/vaccines9090989
   Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, et al. Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis. 2022;75(8):1442–1445. doi:10.1093/cid/ciac288
   PubMed Web of Science ®Google Scholar
• Ma A, Parry J. When Hong Kong’s “dynamic zero” covid-19 strategy met omicron, low vaccination rates sent deaths soaring. BMJ. 2022;377:o980. doi:10.1136/bmj.o980
   PubMedGoogle Scholar
• Siu JY, Cao Y, Shum DHK. Perceptions of and hesitancy toward COVID-19 vaccination in older Chinese adults in Hong Kong: a qualitative study. BMC Geriatr. 2022;22(1):288. doi:10.1186/s12877-022-03000-y
   PubMed Web of Science ®Google Scholar
• Chan SM, Chung GK, Chan YH, et al. Resilience and coping strategies of older adults in Hong Kong during COVID-19 pandemic: a mixed methods study. BMC Geriatr. 2022;22(1):299. doi:10.1186/s12877-022-03009-3
   PubMed Web of Science ®Google Scholar
• HA Central Committee on Infectious Diseases and Emergency Response (CCIDER). Interim Recommendation on Clinical Management of Adult Cases with Coronavirus Disease 2019 (COVID-19). CCIDER; 2022.
   Google Scholar
• So H, Li T, Chan V, Tam LS, Chan PK. Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022;14:1759720X221089586. doi:10.1177/1759720X221089586
   Web of Science ®Google Scholar
• Szebeni GJ, Gemes N, Honfi D, et al. Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study. Front Immunol. 2022;13:846248. doi:10.3389/fimmu.2022.846248
   Web of Science ®Google Scholar
• Ciampi E, Uribe-San-Martin R, Soler B, et al. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;59:103690. doi:10.1016/j.msard.2022.103690
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Baba C, Dogan Y, Cevik S, Ozcelik S, Kaya E. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Mult Scler Relat Disord. 2022;58:103486. doi:10.1016/j.msard.2022.103486
   PubMed Web of Science ®Google Scholar
• Zee JST, Lai KTW, Ho MKS, et al. Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses. Hong Kong Med J. 2021;27(5):380–383. doi:10.12809/hkmj219744
   Web of Science ®Google Scholar
• Sakuraba A, Luna A, Micic D. Serologic response to Coronavirus Disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2022;162(1):88–108 e109. doi:10.1053/j.gastro.2021.09.055
   PubMed Web of Science ®Google Scholar
• Li X, Gao L, Tong X, et al. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: a descriptive cohort study among 1.1 million vaccinated people in Hong Kong. J Autoimmun. 2022;130:102830. doi:10.1016/j.jaut.2022.102830
   PubMed Web of Science ®Google Scholar
• Kwok WC, Tam AR, Ho JCM, et al. Asthma, from mild to severe, is an independent prognostic factor for mild to severe coronavirus disease 2019 (COVID-19). Clin Respir J. 2022;16(4):293–300. doi:10.1111/crj.13480
   PubMed Web of Science ®Google Scholar
• Rainer L, Bachner F, Eglau K, Ostermann H, Siebert U, Zuba M. Comorbidities and COVID-19 hospitalization, ICU admission and hospital mortality in Austria: a retrospective cohort study. Wien Klin Wochenschr. 2022;134(23–24):856–867. doi:10.1007/s00508-022-02036-9
   Web of Science ®Google Scholar
• Graziani D, Soriano JB, Del Rio-Bermudez C, et al. Characteristics and prognosis of COVID-19 in patients with COPD. J Clin Med. 2020;9(10):3259. doi:10.3390/jcm9103259
   PubMed Web of Science ®Google Scholar
• Gomez Antunez M, Muino Miguez A, Bendala Estrada AD, et al. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis. 2021;15:3433–3445. doi:10.2147/COPD.S276692
   PubMed Web of Science ®Google Scholar
• Choi YJ, Park J-Y, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57(3):2002226. doi:10.1183/13993003.02226-2020
   PubMed Web of Science ®Google Scholar
• Mahdavinia M, Foster KJ, Jauregui E, et al. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract. 2020;8(7):2388–2391. doi:10.1016/j.jaip.2020.05.006
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi:10.1038/s41586-020-2521-4
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Rabe AP, Loke WJ, et al. Epidemiology, healthcare resource utilization, and mortality of asthma and COPD in COVID-19: a systematic literature review and meta-analyses. J Asthma Allergy. 2022;15:811–825. doi:10.2147/JAA.S360985
   PubMed Web of Science ®Google Scholar
• Choi H, Lee H, Lee SK, et al. Impact of bronchiectasis on susceptibility to and severity of COVID-19: a nationwide cohort study. Ther Adv Respir Dis. 2021;15:1753466621995043. doi:10.1177/1753466621995043
   Web of Science ®Google Scholar
• Ip MS, Ko FW, Lau AC, et al. Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest. 2006;129(2):384–392. doi:10.1378/chest.129.2.384
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 Clinical Management Living Guidance. Vol. 3. World Health Organization; 2021:116.
   Google Scholar
• Semenzato L, Botton J, Baricault B, et al. Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: a cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the national health data system. PLoS One. 2022;17(9):e0274309. doi:10.1371/journal.pone.0274309
   Web of Science ®Google Scholar
• Yan VKC, Wan EYF, Ye X, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 omicron BA.2 infection: a case-control study. Emerg Microbes Infect. 2022;11(1):2304–2314. doi:10.1080/22221751.2022.2114854
   PubMed Web of Science ®Google Scholar
• McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–1443. doi:10.1016/S1473-3099(22)00345-0
   PubMed Web of Science ®Google Scholar